CPC C12Q 1/6883 (2013.01) [C12Q 1/70 (2013.01); C12Q 1/701 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/26 (2013.01)] | 13 Claims |
1. A method for treating a virus-associated inflammatory response syndrome (VaSIRS) in a human subject, wherein the human subject has at least one clinical sign of SIRS, the method comprising:
(1) in a blood sample taken from the subject, measuring an expression level for a polynucleotide expression product of ISG15 and an expression level for a polynucleotide expression product of IL16;
(2) determining a derived biomarker value for the blood sample, wherein the derived biomarker value being a ratio of the expression level of the polynucleotide expression product of ISG15 to the expression level of the polynucleotide expression product of IL16;
(3) determining whether the derived biomarker value for the blood sample is greater than a reference derived biomarker value determined from expression levels for the polynucleotide expression product of ISG15 and the expression levels for the polynucleotide expression product of IL16 in samples from non-VaSIRS control subjects; and
(4) if the derived biomarker value for the blood sample is greater than the reference derived biomarker value, administering to the subject an effective amount of a VaSIRS therapeutic agent.
|